Monthly Archives: September 2016

DURHAM, N.C., SEPTEMBER 29, 2016 — Point-in-time “landmark” analysis, the standard in most chronic pain studies, may not be appropriate for evaluating single-dose drugs. Instead, an analysis strategy similar to that used in acute-pain research may be more effective, Premier Research’s top biostatistics expert will assert in a poster presentation at the American Statistical Association’sRead more

“Speed without quality – like the quality of a swimmer’s stroke during a race – just doesn’t get you the win that you’re aiming for.” – Krista Armstrong, VP for Strategic Development Krista was talking about quality in patient recruitment in our latest webinar, but really it’s a thought that covers all areas of psychiatric clinicalRead more

DURHAM, N.C., September 16, 2016 — Premier Research has named Dr. Howard Welgus Medical Director to lead dermatology research, building on the company’s existing dermatology study offerings to innovative biopharmaceutical companies. Dr. Welgus brings to this new role extensive experience in pharmaceutical research and development and academia. Dr. Welgus has supported the development efforts ofRead more

DURHAM, N.C., SEPTEMBER 15, 2016 — Premier Research has named Joanne Emmett Vice President of Medical Devices. She oversees a medical device team that has more than 20 years of experience across a wide range of device categories and has completed more than 200 projects involving 34,000 patients in the past five years alone. EmmettRead more

There are more than 7,000 known rare diseases, and these conditions afflict an estimated 30 million Americans (almost one in 10). Worldwide, some 350 million are living with a rare disease. But for 95 percent of these conditions, there are no FDA-approved treatments — not one. Conventional wisdom holds that innovation follows need: that ifRead more

DURHAM, N.C., SEPTEMBER 1, 2016 — In a perfect world, clinical drug trials draw conclusive results from objective observations. But when the real world falls short of perfection by one of these criteria or both, you may need to make other plans. It’s a common occurrence in psychiatry drug trials, and managing the risks willRead more

No more posts
Phone Us Now
Email Us Now